Loading…
Employees: 210
Size Xvivo Perfusion (XVIVO.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $635M, the 162nd largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 197.50 on 6 Nov 2026.
Performance Over six months the shares fell 29.1%, against -11.8% for the median peer and +8.2% for the Sweden market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 17.8% over the last twelve months (peer median +5.8%); the operating margin is 12.1% (peer median 8.0%).
Valuation It trades at 54.2× forward earnings against a peer median of 23.9× (3rd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.4 points below its cost of capital (9.9% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 959M | SEK 812M | SEK 822M | SEK 598M | SEK 415M |
| Revenue growth | — | -1% | +38% | +44% | — |
| Gross profit | SEK 607M | SEK 533M | SEK 551M | SEK 417M | SEK 283M |
| EBITDA | SEK 199M | SEK 163M | SEK 183M | SEK 69.4M | SEK 34.3M |
| Net income | SEK 129M | SEK 25.2M | SEK 172M | SEK 91.8M | SEK 18.4M |
| Free cash flow | n/a | SEK 7.34M | SEK 40.6M | SEK 3.27M | SEK 9.67M |
| Capital expenditure | n/a | SEK 253M | SEK 193M | SEK 144M | SEK 131M |
| Total debt | SEK 121M | SEK 125M | SEK 34.0M | SEK 31.4M | SEK 10.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XVIVO.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.2% | -0.5% | 6th lowest of 21 |
| 6-month return | -29.1% | -11.8% | 3rd lowest of 21 |
| Distance from 52-week high | -37.3% | -34.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +17.8% | +5.8% | 5th highest of 21 |
| Operating margin | 12.1% | 8.0% | 8th highest of 21 |
| Forward P/E | 54.2× | 23.9× | 3rd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 35.7% | 2.7% | most demanding of 14 |
| Growth delivered (Del g) | +35.2% | +6.7% | highest of 14 |
| Hurdle (Req g minus delivered) | +0.5 pp | -4.2 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | -5.4 pp | +1.2 pp | 6th lowest of 21 |
| EV / EBITDA | 30.4× | 15.0× | 2nd most expensive of 7 |
| Net debt / EBITDA | -1.0× | -1.1× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Beijing Chunlizhengda Medical Instruments 1858.HK | Hong Kong | $671M | -27% | -9% | 31% | 9.2× | -8.0% | +1.5% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 90.3× | 34.4% | +6.7% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |